MA56350B1 - Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide, et préparation d'acétate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide - Google Patents

Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide, et préparation d'acétate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide

Info

Publication number
MA56350B1
MA56350B1 MA56350A MA56350A MA56350B1 MA 56350 B1 MA56350 B1 MA 56350B1 MA 56350 A MA56350 A MA 56350A MA 56350 A MA56350 A MA 56350A MA 56350 B1 MA56350 B1 MA 56350B1
Authority
MA
Morocco
Prior art keywords
trifluoro
carbonyl
pyridin
piperidine
methyl
Prior art date
Application number
MA56350A
Other languages
English (en)
Inventor
David Andrew Coates
Aktham Aburub
Scott Alan Frank
Mark Steven KERR
Roger Ryan Rothhaar
Radhe Krishan Vaid
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71948732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56350(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA56350B1 publication Critical patent/MA56350B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Les modes de réalisation de la présente invention concernent des procédés et un intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-N-[6-(1-méthylpipéridine-4-carbonyl)-2-pyridyl]benzamide, et des formulations et formes de produits fabriquées par ces procédés. Les modes de réalisation de la présente invention concernent également la préparation d'acétate de lasmiditan, d'un sel d'acétate de 2,4,6-trifluoro-N-[6-(1-méthylpipéridine-4-carbonyl)-2-pyridyl]benzamide, et/ou leurs compositions pharmaceutiques, et/ou des utilisations de l'acétate de lasmiditan et des formulations de ce dernier dans l'administration sous-cutanée de médicament.
MA56350A 2019-07-09 2020-07-06 Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide, et préparation d'acétate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide MA56350B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871965P 2019-07-09 2019-07-09
EP20751396.1A EP3996713B1 (fr) 2019-07-09 2020-07-06 Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide
PCT/US2020/040881 WO2021007155A1 (fr) 2019-07-09 2020-07-06 Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide, et préparation d'acétate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide

Publications (1)

Publication Number Publication Date
MA56350B1 true MA56350B1 (fr) 2025-05-30

Family

ID=71948732

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56350A MA56350B1 (fr) 2019-07-09 2020-07-06 Procédés et intermédiaire de préparation à grande échelle d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide, et préparation d'acétate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridine-2-yl]-benzamide

Country Status (36)

Country Link
US (5) US20230137090A1 (fr)
EP (2) EP3996713B1 (fr)
JP (3) JP7301209B2 (fr)
KR (3) KR20220019772A (fr)
CN (2) CN114144408B (fr)
AR (1) AR119319A1 (fr)
AU (2) AU2020310852B2 (fr)
BR (1) BR112021026219A2 (fr)
CA (2) CA3201026C (fr)
CL (2) CL2022000018A1 (fr)
CO (1) CO2022000062A2 (fr)
CR (1) CR20220005A (fr)
DK (1) DK3996713T3 (fr)
DO (1) DOP2024000099A (fr)
EC (1) ECSP22001538A (fr)
ES (1) ES3006888T3 (fr)
FI (1) FI3996713T3 (fr)
HR (1) HRP20250049T1 (fr)
HU (1) HUE070451T2 (fr)
IL (2) IL289226B2 (fr)
JO (2) JOP20220002B1 (fr)
LT (1) LT3996713T (fr)
MA (1) MA56350B1 (fr)
MD (1) MD3996713T2 (fr)
MX (2) MX2022000372A (fr)
MY (1) MY201447A (fr)
PE (1) PE20220811A1 (fr)
PH (1) PH12022550031A1 (fr)
PL (1) PL3996713T3 (fr)
PT (1) PT3996713T (fr)
RS (1) RS66403B1 (fr)
SA (1) SA522431304B1 (fr)
SI (1) SI3996713T1 (fr)
TW (2) TWI829107B (fr)
WO (1) WO2021007155A1 (fr)
ZA (2) ZA202110805B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
IL307949A (en) 2021-05-07 2023-12-01 Lilly Co Eli 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridine-2-ylg-benzamide hemisuccinate masked flavor compounds, and an orodispersible tablet consisting of the same
CN115594665A (zh) * 2021-07-08 2023-01-13 北京万全德众医药生物技术有限公司（Cn） 拉司米地坦的新制备方法
IT202100023861A1 (it) * 2021-09-16 2023-03-16 Procos Spa Processo per la preparazione di (6-alopiridin-2-il)(1-metilpiperidin-4-il)metanone
CN113866318B (zh) * 2021-10-21 2023-07-04 佛山奕安赛医药科技有限公司 一种(6-氨基吡啶-2-基)(1-甲基哌啶-4-基)甲酮双盐酸盐的检测方法
WO2023152081A1 (fr) * 2022-02-09 2023-08-17 Inke, S.A. Procédé de préparation de pyridinoylpipéridines agonistes de 5-ht1f et sels associés
CN116925037B (zh) * 2022-04-02 2026-04-07 山东新时代药业有限公司 一种2-氨基-6-(1-甲基哌啶-4-基羰基)吡啶的制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
AU702322B2 (en) 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
AU7261196A (en) 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
EP0929299B1 (fr) 1996-08-28 2003-10-08 Eli Lilly And Company 1,2,3,4-tetrahydro-2-dibenzofuranamines substitues et 2-aminocyclo-hepta(b)benzofuranes
WO1998015545A1 (fr) 1996-10-08 1998-04-16 Eli Lilly And Company Nouveaux agonistes de la serotonine 5-ht¿1f?
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (fr) 1997-04-14 1998-11-04 Eli Lilly And Company Composés hétéroaromatiques substitués agonistes du récepteur 5-HT1F
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000000490A2 (fr) 1998-06-26 2000-01-06 Eli Lilly And Company Agonistes de 5-ht¿1f?
DE69912279T2 (de) 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
AU1937300A (en) 1998-12-11 2000-06-26 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
JP2002536434A (ja) 1999-02-10 2002-10-29 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
KR20010102355A (ko) 1999-02-26 2001-11-15 피터 지. 스트링거 5-ｈｔ1ｆ 효능제
KR100849981B1 (ko) 2000-07-13 2008-08-01 메르크 파텐트 게엠베하 키랄 화합물 ｉ
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
WO2003000245A1 (fr) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Composes destines a etre utilises dans des troubles associes a l'activite des mastocytes ou des basophiles
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2004099127A1 (fr) 2003-05-07 2004-11-18 Novo Nordisk A/S Composes utilises comme inhibiteurs de kinase
WO2005007621A2 (fr) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Inhibiteurs de ligase d'ubiquitine
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (fr) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques
CA2588517A1 (fr) 2004-12-01 2006-06-08 Devgen N.V. Derives de thiazole substitue par du 5-carboxamido qui interagissent avec des canaux ioniques, en particulier avec des canaux ioniques de la famille de kv
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2011123654A1 (fr) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions et méthodes de synthèse d'agonistes des récepteurs 5-ht1f dérivés de la pyridinoylpipéridine
WO2012163365A1 (fr) 2011-06-01 2012-12-06 Concit Pharma Aps Combinaisons d'agonistes de récepteur de sérotonine pour le traitement de troubles du mouvement
US9874470B2 (en) * 2016-01-12 2018-01-23 Tank Vision, Inc. Fuel tank level monitoring system
CN113149959A (zh) * 2016-07-15 2021-07-23 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
JOP20190129B1 (ar) * 2016-12-06 2023-03-28 Colucid Pharmaceuticals Inc تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Also Published As

Publication number Publication date
JP7301209B2 (ja) 2023-06-30
PE20220811A1 (es) 2022-05-20
JP2023089110A (ja) 2023-06-27
AU2023201473B2 (en) 2023-10-19
HRP20250049T1 (hr) 2025-03-14
MD3996713T2 (ro) 2025-05-31
TW202116749A (zh) 2021-05-01
CA3201026C (fr) 2025-06-10
PH12022550031A1 (en) 2022-11-21
RS66403B1 (sr) 2025-02-28
LT3996713T (lt) 2025-02-25
MX2023003230A (es) 2023-04-14
SA522431304B1 (ar) 2024-08-05
EP3996713A1 (fr) 2022-05-18
JOP20220002A1 (ar) 2023-01-30
CA3201026A1 (fr) 2021-01-14
DOP2024000099A (es) 2024-06-16
PT3996713T (pt) 2025-01-21
IL314421A (en) 2024-09-01
CL2022000018A1 (es) 2022-09-30
ZA202110805B (en) 2025-01-29
KR20240027877A (ko) 2024-03-04
ES3006888T3 (en) 2025-03-19
CL2023003040A1 (es) 2024-05-03
US20230137090A1 (en) 2023-05-04
PL3996713T3 (pl) 2025-03-10
EP3996713B1 (fr) 2024-12-04
TWI776175B (zh) 2022-09-01
ECSP22001538A (es) 2022-02-25
MY201447A (en) 2024-02-22
CA3146129A1 (fr) 2021-01-14
JP2025066745A (ja) 2025-04-23
DK3996713T3 (da) 2025-02-24
CN114144408A (zh) 2022-03-04
US11827618B2 (en) 2023-11-28
BR112021026219A2 (pt) 2022-02-15
HUE070451T2 (hu) 2025-06-28
US20240059666A1 (en) 2024-02-22
IL289226B1 (en) 2025-01-01
FI3996713T3 (fi) 2025-02-21
ZA202303699B (en) 2024-09-25
CN120441536A (zh) 2025-08-08
AR119319A1 (es) 2021-12-09
IL289226A (en) 2022-02-01
US20230250075A1 (en) 2023-08-10
US12071423B2 (en) 2024-08-27
AU2020310852A1 (en) 2022-01-20
JP2022540140A (ja) 2022-09-14
CN114144408B (zh) 2025-04-15
JP7660604B2 (ja) 2025-04-11
KR20220019772A (ko) 2022-02-17
EP4410784A2 (fr) 2024-08-07
MX2022000372A (es) 2022-02-10
CA3146129C (fr) 2023-12-12
EP4410784A3 (fr) 2025-01-22
WO2021007155A1 (fr) 2021-01-14
NZ783764A (en) 2025-03-28
IL289226B2 (en) 2025-05-01
JOP20240254A1 (ar) 2024-11-10
TWI829107B (zh) 2024-01-11
AU2023201473A1 (en) 2023-04-13
SI3996713T1 (sl) 2025-04-30
CR20220005A (es) 2022-02-14
TW202225148A (zh) 2022-07-01
CO2022000062A2 (es) 2022-01-17
US20230250076A1 (en) 2023-08-10
IL314421B1 (en) 2025-11-01
IL314421B2 (en) 2026-03-01
AU2020310852B2 (en) 2023-04-13
KR20240162595A (ko) 2024-11-15
JOP20220002B1 (ar) 2025-10-01
US20250019363A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
MX2025000772A (es) Compuesto heterociclico que actua sobre la proteina kras mutante g12d
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
Chu et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas
EP4306523A3 (fr) Composés d&#39;imidazoquinoléine et leurs utilisations
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
WO2019244066A3 (fr) Dérivés d&#39;acide pyridin-3-yl-acétique en tant qu&#39;inhibiteurs de la réplication du virus de l&#39;immunodéficience humaine
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d&#39;utilisation de ces dernières
AU2018277520A1 (en) 6-5 fused rings as C5a inhibitors
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
ATE384724T1 (de) Cyclopropylverbindungen als ccr5 antagonisten
EP4603148A3 (fr) Pirfénidone enrichie en deutérium et ses procédés d&#39;utilisation
EP4282414A3 (fr) Formulations de comprimés à libération modifiée contenant des inhibiteurs de phosphodiestérase
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
BR112021025236A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina
MX2022006489A (es) Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
MX2022004014A (es) Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso.